Agilent (A) announced its PD-L1 IHC 22C3 pharmDx assay has received European IVDR certification for the use as a Companion Diagnostic to aid in the identification of gastric or gastroesophageal Junction adenocarcinoma patients who may be eligible for treatment with Keytruda. PD-L1 IHC 22C3 pharmDx is approved for exclusive use with the Agilent Autostainer Link 48 advanced staining solution.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A: